<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="199163">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00497783</url>
  </required_header>
  <id_info>
    <org_study_id>LACTO_L_02949</org_study_id>
    <nct_id>NCT00497783</nct_id>
  </id_info>
  <brief_title>Acceptability Lactoserum (Dermacyd Delicata - New Fragrance)</brief_title>
  <official_title>Safety Dermatological Evaluation of the Acceptability With Gynecological Follow up for Dermacyd Femina Delicata</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the safety of the gynecological formulation in
      normal and usual usage condition of Dermacyd Femina Delicata.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical and local tolerability</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events and their association with the treatment.</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hygiene</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactoserum</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Integral skin in the tested region

        Exclusion Criteria:

          -  Pregnancy or breastfeeding women

          -  Use of Anti-inflammatory or immune-suppression drugs

          -  Topical medication use at the tested region

          -  Active cutaneous gynaecological disease which may interfere in study results

          -  Personal history of allergic disease at the area to be treated

          -  Allergic or atopic history

        The above information is not intended to contain considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaderson Lima</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-aventis</name>
      <address>
        <city>SÃ£o Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <lastchanged_date>May 19, 2008</lastchanged_date>
  <firstreceived_date>July 6, 2007</firstreceived_date>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
